We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Indications -- Hepatitis
An SI Board Since March 2001
Posts SubjectMarks Bans
305 29 0
Emcee:  tuck Type:  Unmoderated
Hepatitis is a worldwide epidemic, and a lot of companies are working on better treatments.

This is the most helpful link I've found for an overview for the U.S. (in case it expires, I've taken the liberty of excerpting a bit):

>>Chronic Viral Hepatitis in the United States

Norah Terrault, MD, MPH
University of California

San Francisco, California

Key Concepts:

- Chronic liver disease, including cirrhosis, represents the 10th most common cause of death in the U.S. Viral hepatitis is the commonest cause of chronic liver disease with an estimated 1.25 million, 2.7 million and 70,000 individuals with chronic hepatitis B virus (HBV), hepatitis C virus (HCV) and hepatitis D virus (HDV) infection, respectively.

- In the U.S., the prevalence of markers of past or chronic HBV infection is low until age 12, increasing thereafter, and is similar among males and females. The factors associated with chronic HBV infection are ethnicity (highest in non-Hispanic blacks), number of sexual partners, marital status, foreign birth, level of education, and illicit drug use.

- In the U.S., chronic HCV infection is more common in males than females and the peak prevalence is in those aged 30-39 years. HCV alone or in combination with alcohol accounts for about (60% of newly diagnosed cases of chronic liver disease.

- The prevalence of HDV in the U.S. is low. The groups with the highest prevalence of infection are injection drug users and multiply-transfused individuals (e.g. hemophiliacs).

- The risk factors for acquisition of HBV, HCV and HDV are well-established. Understanding the modes of transmission is critical in designing prevention strategies to reduce the burden of chronic liver disease.

- The geographical distribution of viral genotypes of HBV, HCV and HDV are known. Correlations between specific viral genotypes and clinical outcomes, such as disease severity and response to anti-viral treatments, are under study.<<

For the international scene check



Some other helpful links:

Monty's Page of HCV Drugs in Development

American Association for the Study of Liver Disease (you'll have to subscribe for much useful stuff, but there are a few freebies)

Hepatitis Information Network (HepNet):

CDC's Hepatitis Page:

University of Washington's Hepatitis Web Study Pages (starting at Hep C, with links to others:

This is my contribution so far to the idea of launching threads specific to indications and their markets and companies. You're welcome. Have at it!
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
305ENTA disclosed the royalty-rate tiers for Mavyret/Glecaprevir: twitter.comDewDiligence_on_SI-8/9/2018
304My estimation is that 2/3 of the raised guidance pertains to ex-US uptake. DewDiligence_on_SI-4/26/2018
303What part of that raise is for US? Too lazy to listen CC! It was predictable thaMiljenko Zuanic-4/26/2018
302(ENTA)—ABBV raises 2018 HCV sales guidance (almost all Mavyret) from $2.5B to $3DewDiligence_on_SI-4/26/2018
301Mavyret's NRx% and TRx% are already above what most sell-side analysts thougDewDiligence_on_SI-2/16/2018
300Congratulation! [eom]Miljenko Zuanic-2/5/2018
299ENTA price chart is starting to look like the Mavyret script chart.DewDiligence_on_SI-2/5/2018
298Agree, do think that GLPG is right choice, but they may want to stay independentMiljenko Zuanic-2/4/2018
297GLPG... Its probably not going to happen because everyone thinks its inevitable ghmm-2/3/2018
296No, I don't (sorry).DewDiligence_on_SI-2/3/2018
295Yes, have anyone in mind? Would like to make few $$$!Miljenko Zuanic-2/3/2018
294Another large acquisition by GILD during 2018 seems pretty likely.DewDiligence_on_SI-2/3/2018
293The power of the WS price, marketing adaptability, and good activity. GILD HCV fMiljenko Zuanic-2/3/2018
292Chart of weekly HCV scripts shows Mavyret's blastoff: twitter.comDewDiligence_on_SI-2/3/2018
291HCV notes from ABBV's 4Q17 CC: investorshub.advfn.comDewDiligence_on_SI-1/26/2018
290(ACHN/Medivir)—JNJ throws in the towel on HCV: investorshub.advfn.comDewDiligence_on_SI-9/11/2017
289FDA approves ABBV/ENTA’s Mavyret (G/P)—8-week treatment for all HCV genotypes: sDewDiligence_on_SI-8/3/2017
288ICPT data from 'CONTROL' study with Lipitor not especially impressive, IDewDiligence_on_SI-7/31/2017
287Looks like an even match, IMO. Good situation for third-party payers and ex-US gDewDiligence_on_SI-7/28/2017
286So, Vosevi still have slight/small advantage over Maviret. But, as I mentioned oMiljenko Zuanic-7/28/2017
285European Commission approves GILD’s Vosevi and ABBV/ENTA’s Maviret, direct compeDewDiligence_on_SI-7/28/2017
284ABBV/ENTA’s G/P receives early-access approval in UK for hard-to-treat patients:DewDiligence_on_SI-5/11/2017
283JNJ/ACHN's 3-DAA regimen has a problem: siliconinvestor.comDewDiligence_on_SI-4/22/2017
282MRK’s 3-DAA HCV regimen fails to impress (IMO): siliconinvestor.comDewDiligence_on_SI-11/13/2016
281HCV DAAs can reactivate (latent) HBV, says FDA: fda.govDewDiligence_on_SI-10/4/2016
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):